Cost-effectiveness analysis of human papillomavirus-vaccination programs to prevent cervical cancer in Austria

Vaccine

Volumn 27, Issue 37, 2009, Pages 5133-5141

  Zechmeister, Ingrid ^a   Blasio, Birgitte Freiesleben de ^b   Garnett, Geoff ^c   Neilson, Aileen Rae ^d   Siebert, Uwe ^e,f,g  

^a LUDWIG BOLTZMANN INSTITUTE FOR LUNG VASCULAR RESEARCH   (Austria)

^b UNIVERSITY OF OSLO   (Norway)

^c IMPERIAL COLLEGE LONDON   (United Kingdom)

^d Norwegian Knowledge Centre for Health Services   (Norway)

^e UNIVERSITY FOR HEALTH SCIENCES   (Austria)

^f HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^g MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Cervical cancer screening; Cost effectiveness; HPV vaccination

Indexed keywords

WART VIRUS VACCINE;

ARTICLE; AUSTRIA; CANCER SCREENING; CHILD; COST EFFECTIVENESS ANALYSIS; DRUG COST; FEMALE; HUMAN; MALE; MONEY; OUTCOMES RESEARCH; PREDICTION; PRIORITY JOURNAL; SCHOOL CHILD; UTERINE CERVIX CANCER; VIRUS TRANSMISSION;

AUSTRIA; CHILD; COST-BENEFIT ANALYSIS; FEMALE; HUMANS; IMMUNIZATION PROGRAMS; MALE; MASS SCREENING; MODELS, ECONOMIC; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; SENSITIVITY AND SPECIFICITY; UTERINE CERVICAL NEOPLASMS;

EID: 67650966670     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2009.06.039     Document Type: Article

References (44)

1. Ferlay J., Bray F., Pisani P., and Parkin D.M. GLOBCAN 2002 cancer incidence. mortality and prevalence worldwide. IARC Cancerbase no 5 version 20 (2004), IARC Press, Lyon
2. Statistik Austria. Jahrbuch der Gesundheitsstatistik. Wien: Statistik Austria; 2007.
3. Hauptverband der österreichischen Sozialversicherungsträger. Datenerhebung Pap-Abstrich. Wien: Hauptverband der österreichischen Sozialversicherungsträger; 2007.
4. National Board of Health, Danish Centre for Health Technology Assessement. Reduction in the risk of cervical cancer by vaccination against human papillomavirus (HPV)-a health technology assessment. Copenhagen: National Board of Health, Danish Centre for Health Technology Assessment; 2007.
5. Thiry N., Lambert M.-L., Cleemput I., Huybrechts M., Neyt M., Hulstaert F., et al. HPV Vaccination for the prevention of cervical cancer in belgium: health technology assessment (2007), Belgian Health Care Knowledge Centre (KCE), Brussels
6. Nielsen E., Alfsen G.C., Feiring B., Skjeldestad F.E., Steen R., and Saeterdal I. Prophylactic vaccines against human papillomavirus (2007), Norwegian Knowledge Centre for the Health Services, Oslo
7. Siebert U. When should decision-analytic modeling be used in the economic evaluation of health care?. European Journal of Health Economics 4 (2003) 143-150
8. Kulasingam S.L., Benard S., Barnabas R.V., Largeron N., and Myers E.R. Adding a quadrivalent human papillomavirus vaccine to the UK cervical cancer screening programme: a cost-effectiveness analysis. Cost Effectiveness and Resource Allocation 6 (2008) 4
9. Kulasingam S.L., and Myers E.R. Potential health and economic impact of adding a human papillomavirus vaccine to screening programs. Journal of the American Medical Association 290 6 (2003) 781-789
10. Kim J., and Goldie S. Health and economic implications of HPV vaccination in the United States. New England Journal of Medicine 359 8 (2008) 821-832
11. Goldie S.J., Kim J.J., Kobus K., Goldhaber-Fiebert J.D., Salomon J., O'Shea M.K.H., et al. Cost-effectiveness of HPV 16, 18 vaccination in Brazil. Vaccine 25 (2007) 6257-6270
12. Goldie S.J., Kohli M., Grima D., Weinstein M.C., Wright T.C., Bosch F.X., et al. Projected clinical benefits and cost-effectiveness of a human papillomavirus 16/18 vaccine. Journal of the National Cancer Institute 96 8 (2004) 604-615
13. Insinga R., Dasbach E.J., Elbahsa E.H., Puig A., and Reynales-Shigematsu L.M. Cost-effectiveness of quadrivalent human papillomavirus (HPV) vaccination in Mexico: a transmission dynamic model-based evaluation. Vaccine 26 (2007) 128-139
14. Jit M., Choi Y.H., and Edmunds W.J. Economic evaluation of human papillomavirus vaccination in the United Kingdom. British Medical Journal 337 (2008) a769
15. Neilson A., and Freiesleben de Blasio B. Economic evaluation of the human papillomavirus (HPV)-vaccination in Norway (2007), Norwegian Knowledge Centre for the Health Services, Oslo
16. Brisson M., Van der Velde N., De Wals P., and Boily M.-C. The potential cost-effectiveness of prophylactic human papillomavirus vaccines in Canada. Vaccine 25 (2007) 5399-5408
17. Bergeron C., Largeron N., McAllister R., Mathevet P., and Remy V. Cost-effectiveness analysis of the introduction of a quadirvalent human papillomavirus vaccine in France. International Journal of Health Technology Assessment in Health Care 24 1 (2008) 10-19
18. Sanders G., and Taira A.V. Cost effectiveness of a potential vaccine for human papillomavirus. Emerging Infectious Diseases 9 1 (2003) 37-48
19. Taira A.V., Neukermans C.P., and Sanders G.D. Evaluating human papillomavirus vaccination programs. Emerging Infectious Diseases 10 11 (2004) 1915-1923
20. Elbasha E.H., Dasbach E.J., and Insinga R.P. Model for assessing human papillomavirus vaccination strategies. Emerging Infectious Diseases 13 1 (2007) 28-41
21. Drummond M., Barbieri M., Cook J., Glick H., Lis J., Malik F., et al. Transferability of economic evaluations across jurisdictions. Value in Health 12 4 (2009) 409-418
22. Welte R., Feenstra T., Jager H., and Leidl R. A decision chart for assessing and improving the transferability of economic evaluation results between countries. Pharmacoeconomics 22 13 (2004) 857-876
23. Zechmeister I., Freiesleben de Blasio B., and Garnett G.P. HPV vaccination for the prevention of cervical cancer in Austria: a model-based long term prognosis on cancer epidemiology. Journal of Public Health (status: submitted in August 2008; accepted May 2009; forthcoming) (2009)
24. Bundesministerium für Gesundheit Familie und Jugend (BMGFJ). Impfstatistik. Wien: Bundesministerium für Gesundheit, Familie und Jugend; Abteilung Infektionskrankheiten, Seuchenbekämpfung und Krisenmanagement; 2007.
25. Statistik Austria. Bevölkerungsstatistik Einzelauswertung. Wien: Statistik Austria; 2007.
26. OECD. GDP deflators for several countries. Paris: OECD; 2007.
27. Walter E., and Zehetmayr S. Guidelines zur gesundheitsökonomischen Evaluation (2006), Institut für Pharmaökonomische Forschung, Wien
28. Hackl M.K. Sonderauswertung (2007), Statistik Austria, Wien
29. Muñoz N., Bosch F., Castellasague X., Díaz M., de Sanjose S., Hammouda D., et al. Against which human paillomavirus types shall we vaccinate and screen?. International Journal of Cancer 111 2 (2004) 278-285
30. Roberts C., Tadesse A., Sands J., Halvorsen T., Schonfield T., Dalen A., et al. Detection of HPV in Norwegian cervical biopsy specimens with type-specific PCR and reverse line blot assays. Clinical Virology 36 (2006) 277-282
31. Roehr B. HPV Vaccine Provides Cross-Protection Against Other Strains. Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC); 2007; San Francisco; 2007.
32. Gold M.R., Siegel J.E., Russel L.B., and Weinstein M.C. Cost-effectiveness in health and medicine (1996), Oxford University Press, New York
33. In: Drummond M., Sculpher M., Torrance G.W., O'Brien B., and Stoddart G.L. (Eds). Methods for the economic evaluation of health care programmes. 3rd ed. (2005), Oxford University Press, New York
34. Dören M, A G, Gerlach F, Hornberg C, Kochen M, Kolip P, et al. Wissenschaftler/innen fordern Neubewertung der HPV-Impfung und ein Ende der irreführenden Informationen. Bielefeld: Universität Bielefeld 2008.
35. Kim J., Kuntz K., Mahmud N.S., Villa S., Franco L.L., et al. Multiparameter calibration of a natural history model of cervical cancer. American Journal of Epidemiology 166 (2007) 137-150
36. Ho G.Y., Bierman R., Beardsley L., Chang C.J., and Burk R.D. Natural history of cervicovaginal papillomavirus infection among cytologically normal women. New England Journal of Medicine 338 (1998) 423-428
37. Muñoz N., Mendez F., Posso H., Molano M., van den Brule A.J., Ronderos M., et al. Incidence, duration, and determination of cervical human papillomavirus infection in a cohort of Columbian women with normal cytological results. Journal of Infectious Disease 190 (2004) 2077-2087
38. Vutuc C., Haidinger G., Waldhoer T., Ahmad F., and Breitenecker G. Prevalence of self-reported cervical cancer screening and impact on cervical cancer mortality in Austria. Wiener Klinische Wochenschrift 111 9 (1999) 354-359
39. Coste J., Cochand-Priollet B., de Cremoux P., Le Galés C., Cartier I., Molinié V., et al. Cross sectional study of conventional cervical smear, monolayer cytology, and human papillomavirus DNA testing for cervical cancer screening. British Medical Journal 326 (2003) 733
40. Hauptverband der österreichischen Sozialversicherungsträger. Honorarordnungsdatenbank - Einzelauswertung. Wien: Hauptverband der österreichischen Sozialversicherungsträger; 2007.
41. Bundesministerium für Gesundheit Familie und Jugend. LKF-Statistik - Einzelauswertung. Wien: Bundesministerium für Gesundheit, Familie und Jugend; 2007.
42. Rechnungshof. Einkommensbericht 2006/1. Wien: Rechnungshof 2006.
43. Statistik Austria. Arbeitsmarktstatistik. Wien: Statistik Austria; 2007.
44. Hauptverband der österreichischen Sozialversicherungsträger. Österreichische Sozialversicherung in Zahlen 2006. Wien: Hauptverband der österreichischen Sozialversicherungsträger; 2007.